



*Virtual Conference*

# The 11<sup>th</sup> Asia-Pacific Primary Liver Cancer Expert Meeting

August 13-15, 2021 | [www.applecongress.org](http://www.applecongress.org)



# APPLE ACADEMY 2021



## PROGRAM AT A GLANCE

GMT+09:00 (Seoul, Tokyo)

| Friday, August 13, 2021 |                                                                                     |
|-------------------------|-------------------------------------------------------------------------------------|
| ROOM 1                  |                                                                                     |
| 11:00                   |                                                                                     |
| 12:00                   | Opening (11:50-12:00)                                                               |
| 13:00                   | <b>Session 1</b><br>Risk Factors, Surveillance, and Prevention<br>(12:00-13:00)     |
| 14:00                   | <b>Session 2</b><br>Diagnosis and Staging for HCC and CC<br>(13:10-14:10)           |
| 15:00                   | <b>Session 3</b><br>Liver-Directed Therapy<br>(14:20-15:35)                         |
| 16:00                   | <b>Session 4</b><br>System Treatment for HCC and CC<br>(15:50-16:50)                |
| 17:00                   | Closing Remarks (16:50-17:00)<br>APPLE Academy Satellite Symposium<br>(17:00-17:30) |
| 18:00                   |                                                                                     |

## SCIENTIFIC PROGRAM

GMT+09:00 (Seoul, Tokyo) FRIDAY, AUGUST 13, 2021

|                    |                                                                                                       |                                                                     |
|--------------------|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| 11:50-12:00        | Opening                                                                                               | <i>Jinsil Seong (President)</i>                                     |
| <b>12:00-13:00</b> | <b>Session 1. Risk Factors, Surveillance and Prevention</b>                                           | <i>Namiki Izumi (Musashino Red Cross Hospital, Tokyo)</i>           |
| 12:00-12:15        | Risk Factors and Prevention (Primary, Secondary, Tertiary)                                            | <i>Junqi Niu (Jilin Univ., Jilin)</i>                               |
| 12:15-12:30        | Biomarkers for HCC and CC                                                                             | <i>Kwang-Hyub Han (NECA, Seoul)</i>                                 |
| 12:30-12:45        | Current Recommendation for Surveillance                                                               | <i>Young-Suk Lim (Univ. of Ulsan, Seoul)</i>                        |
| 12:45-13:00        | Discussion                                                                                            |                                                                     |
| 13:00-13:10        | Break                                                                                                 |                                                                     |
| <b>13:10-14:10</b> | <b>Session 2. Diagnosis and Staging for HCC and CC</b>                                                | <i>Hirohisa Yano (Kurume Univ., Kurume)</i>                         |
| 13:10-13:25        | Pathological Diagnosis for HCC and CC: New WHO Classification                                         | <i>Irene Ng (The Univ. of Hong Kong, Hong Kong)</i>                 |
| 13:25-13:40        | Imaging for HCC and CC: Diagnosis and Response Evaluation                                             | <i>Choon Hua Thng (National Cancer Centre Singapore, Singapore)</i> |
| 13:40-13:55        | Treatment Algorithm of Current Guidelines for HCC                                                     | <i>Ann-Lii Cheng (National Taiwan Univ., Taipei)</i>                |
| 13:55-14:10        | Case Discussion                                                                                       |                                                                     |
| 14:10-14:20        | Break                                                                                                 |                                                                     |
| <b>14:20-15:35</b> | <b>Session 3. Liver-Directed Therapy</b>                                                              | <i>Pierce Chow (National Cancer Centre Singapore, Singapore)</i>    |
| 14:20-14:35        | Surgical Resection: Update for HCC and CC                                                             | <i>Kyung-Suk Suh (Seoul National Univ., Seoul)</i>                  |
| 14:35-14:50        | Liver Transplantation: Selection Criteria & Outcomes                                                  | <i>Albert Chan (The Univ. of Hong Kong, Hong Kong)</i>              |
| 14:50-15:05        | Transarterial Chemoembolization (TACE)                                                                | <i>Jin Wook Chung (Seoul National Univ., Seoul)</i>                 |
| 15:05-15:20        | Local Therapy Radiotherapy for HCC                                                                    | <i>Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei)</i>       |
| 15:20-15:35        | Case Discussion                                                                                       |                                                                     |
| 15:35-15:50        | Break                                                                                                 |                                                                     |
| <b>15:50-16:50</b> | <b>Session 4. Systemic Treatment for HCC and CC</b>                                                   | <i>Chiun Hsu (National Taiwan Univ., Taipei)</i>                    |
| 15:50-16:05        | Systemic Therapy for HCC                                                                              | <i>Han Chong Toh (National Cancer Centre Singapore, Singapore)</i>  |
| 16:05-16:20        | Systemic Therapy for CC                                                                               | <i>Stephen Lam Chan (The Chinese Univ. of Hong Kong, Hong Kong)</i> |
| 16:20-16:35        | Clinical Trial Design and Analysis: Lessons from Trials of Targeted Therapy and Immunotherapy for HCC | <i>Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)</i> |
| 16:35-16:50        | Discussion                                                                                            |                                                                     |
| 16:50-17:00        | Closing Remarks                                                                                       | <i>Irene Ng and Chiun Hsu (Education Chairs)</i>                    |
| 17:00-17:30        | APPLE Academy Satellite Symposium                                                                     |                                                                     |

## APPLE ACADEMY 2021

*This program is expected to become a stepping stone for our next generation of doctors and non-expert doctors who are interested in liver cancer.*



# The 11<sup>th</sup> Asia-Pacific Primary Liver Cancer Expert Meeting

## PROGRAM AT A GLANCE

GMT+09:00 (Seoul, Tokyo)

| Saturday, August 14, 2021 |                                                                                                      |                                                                                     |
|---------------------------|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|                           | ROOM 1                                                                                               | ROOM 2                                                                              |
| 08:00                     |                                                                                                      |                                                                                     |
| 09:00                     | <b>Session 1</b><br>Epidemiology and Surveillance of HCC<br>(08:30-10:00)                            |                                                                                     |
| 10:00                     | Opening Remark (10:10-10:20)                                                                         |                                                                                     |
|                           | Presidential Lecture<br>(10:20-10:50)                                                                |                                                                                     |
| 11:00                     |                                                                                                      |                                                                                     |
|                           | <b>Session 2</b><br>Surgery and Liver<br>Transplantation of HCC<br>(11:00-12:30)                     | <b>Session 3</b><br>Antiviral Therapy and HCC<br>(11:00-12:30)                      |
| 12:00                     |                                                                                                      |                                                                                     |
|                           | Satellite Symposium - Eisai<br>(12:30-13:10)                                                         | Satellite Symposium - J&J and Hengrui<br>(12:30-13:10)                              |
| 13:00                     |                                                                                                      |                                                                                     |
|                           | <b>Session 4</b><br>Locoregional Therapy for HCC:<br>New Roles in Immunotherapy Era<br>(13:10-14:40) | <b>Session 5</b><br>Molecular Pathogenesis and<br>Pathology of HCC<br>(13:10-14:30) |
| 14:00                     |                                                                                                      |                                                                                     |
|                           | <b>Session 6</b><br>Systemic Therapy for<br>Earlier-Stages of HCC<br>(14:50-15:45)                   | <b>Session 7</b><br>Imaging Diagnosis of HCC<br>(14:50-16:10)                       |
| 15:00                     |                                                                                                      |                                                                                     |
|                           | <b>State-of-the-Art Lecture 1</b><br>(15:55-16:35)                                                   |                                                                                     |
| 16:00                     |                                                                                                      |                                                                                     |
|                           | APPLE General Assembly<br>(16:40-17:20)                                                              |                                                                                     |
| 17:00                     | Satellite Symposium - Roche<br>(17:20-18:00)                                                         |                                                                                     |
| 18:00                     |                                                                                                      |                                                                                     |

|                    |                                                                                                      |                                                                                                                   |
|--------------------|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| <b>08:30-10:00</b> | <b>Session 1. Epidemiology and Surveillance of HCC</b>                                               | <i>Takuji Torimura (Kurume Univ., Kurume),<br/>Do Young Kim (Yonsei Univ., Seoul)</i>                             |
| 08:30-08:50        | Global Epidemiology and Risk Factors of HCC                                                          | <i>Man-Fung Yuen (The Univ. of Hong Kong, Hong Kong)</i>                                                          |
| 08:50-09:10        | HCC in Patients with NASH: Epidemiology, Risk Factors, and Surveillance                              | <i>Ryosuke Tateishi (The Univ. of Tokyo, Tokyo)</i>                                                               |
| 09:10-09:30        | Cost-Effectiveness of HCC Surveillance                                                               | <i>Amit Singal (UT Southwestern Medical Center, Texas)</i>                                                        |
| 09:30-09:50        | Outcome of National HCC Surveillance Program in Korea                                                | <i>Do Young Kim (Yonsei Univ., Seoul)</i>                                                                         |
| 09:50-10:00        | Discussion                                                                                           |                                                                                                                   |
| 10:00-10:10        | Break                                                                                                |                                                                                                                   |
| 10:10-10:20        | Opening Remark                                                                                       |                                                                                                                   |
| <b>10:20-10:50</b> | <b>Presidential Lecture</b>                                                                          | <i>Ann-Lii Cheng (National Taiwan Univ., Taipei)</i>                                                              |
|                    | Radiotherapy of HCC: From Palliation to Cure                                                         | <i>Jinsil Seong (Yonsei Univ., Seoul)</i>                                                                         |
| 10:50-11:00        | Break                                                                                                |                                                                                                                   |
| <b>11:00-12:30</b> | <b>Session 2. Surgery and Liver Transplantation of HCC</b>                                           | <i>Etsuro Hatano (Kyoto Univ., Hyogo),<br/>Linda Wong (Univ. of Hawaii, Hawaii)</i>                               |
| 11:00-11:20        | The Updates and Future of Liver Surgery in the New Eras of TKI Drug and Immunotherapy                | <i>Kiyoshi Hasegawa (The Univ. of Tokyo, Tokyo)</i>                                                               |
| 11:20-11:40        | Surgical Management of HCC beyond the BCLC Guidelines                                                | <i>Tan To Cheung (The Univ. of Hong Kong, Hong Kong)</i>                                                          |
| 11:40-12:00        | Minimally Invasive LDLT                                                                              | <i>Kyung-Suk Suh (Seoul National Univ., Seoul)</i>                                                                |
| 12:00-12:20        | Precision Therapies in Liver Transplantation for Cancer Recurrence: Biology, Genomics and Immunology | <i>Jian Zhou (Fudan Univ., Shanghai)</i>                                                                          |
| 12:20-12:30        | Discussion                                                                                           |                                                                                                                   |
| 12:30-13:10        | Satellite Symposium - Eisai                                                                          |                                                                                                                   |
| <b>13:10-14:40</b> | <b>Session 4. Locoregional Therapy for HCC: New Roles in Immunotherapy Era</b>                       | <i>Namiki Izumi (Musashino Red Cross Hospital, Tokyo),<br/>Guohong Han (Fourth Military Medical Univ., Xi'an)</i> |
| 13:10-13:30        | Chemoembolization: Changing Role in the Real World with Introduction of New Systemic Agents          | <i>Toshihiro Tanaka (Nara Medical Univ., Kashihara)</i>                                                           |
| 13:30-13:50        | Future Role of Locoregional Therapy for HCC: Hepatologist's Perspective                              | <i>Joong-Won Park (National Cancer Center Korea, Goyang)</i>                                                      |
| 13:50-14:10        | Local Radiotherapy as an Immunomodulator in HCC                                                      | <i>Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei)</i>                                                     |
| 14:10-14:30        | Abscopal Effects of Radiotherapy in HCC                                                              | <i>Hee Chul Park (Sungkyunkwan Univ., Seoul)</i>                                                                  |
| 14:30-14:40        | Discussion                                                                                           |                                                                                                                   |
| 14:40-14:50        | Break                                                                                                |                                                                                                                   |

|                    |                                                                                            |                                                                                                                                    |
|--------------------|--------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| <b>14:50-15:45</b> | <b>Session 6.<br/>Systemic Therapy for Earlier-Stages of HCC</b>                           | <i>Pierce Chow (National Cancer Centre Singapore, Singapore),<br/>Stephen Lam Chan (The Chinese Univ. of Hong Kong, Hong Kong)</i> |
| 14:50-15:10        | Role of Systemic Therapy in Early HCC Patients:<br>Hepatologist Perspectives               | <i>Masatoshi Kudo (Kindai Univ., Osaka)</i>                                                                                        |
| 15:10-15:30        | Role of Systemic Therapy in Early HCC Patients:<br>Interventional Radiologist Perspectives | <i>Jin Wook Chung (Seoul National Univ., Seoul)</i>                                                                                |
| 15:30-15:45        | Discussion                                                                                 |                                                                                                                                    |
| 15:45-15:55        | Break                                                                                      |                                                                                                                                    |
| <b>15:55-16:35</b> | <b>State-of-the-Art Lecture 1.</b>                                                         | <i>Ghassan Abou-Alfa (Memorial Sloan-Kettering Cancer Center, New York)</i>                                                        |
|                    | Tumor Immune Microenvironment in HCC                                                       | <i>Tim Greten (National Cancer Institute, Maryland)</i>                                                                            |
| 16:35-16:40        | Break                                                                                      |                                                                                                                                    |
| 16:40-17:20        | APPLE General Assembly                                                                     |                                                                                                                                    |
| 17:20-18:00        | Satellite Symposium - Roche                                                                |                                                                                                                                    |





|                    |                                                                              |                                                                                           |
|--------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| <b>11:00-12:30</b> | <b>Session 3. Antiviral Therapy and HCC</b>                                  | <i>Junqi Niu (Jilin Univ., Jilin), Yong Han Paik (Sungkyunkwan Univ., Seoul)</i>          |
| 11:00-11:20        | Risk Models for HCC Development under Antiviral Therapy in CHB               | <i>Jia-Horng Kao (National Taiwan Univ., Taipei)</i>                                      |
| 11:20-11:40        | Comparison of Tenofovir versus Entecavir on Reducing Incidence of HCC in CHB | <i>Jidong Jia (Beijing Friendship Hospital, Beijing)</i>                                  |
| 11:40-12:00        | Antiviral Therapy in Immune-Tolerant CHB: Pros                               | <i>Young-Suk Lim (Univ. of Ulsan, Seoul)</i>                                              |
| 12:00-12:20        | Antiviral Therapy in Immune-Tolerant CHB: Cons                               | <i>Grace L. H. Wong (The Chinese Univ. of Hong Kong, Hong Kong)</i>                       |
| 12:20-12:30        | Discussion                                                                   |                                                                                           |
| 12:30-13:10        | Satellite Symposium - J&J and Hengrui                                        |                                                                                           |
| <b>13:10-14:30</b> | <b>Session 5. Molecular Pathogenesis and Pathology of HCC</b>                | <i>Michiie Sakamoto (Keio Univ., Tokyo), Irene Ng (The Univ. of Hong Kong, Hong Kong)</i> |
| 13:10-13:30        | Intratumoural Immune Heterogeneity as a Hallmark of Tumour Evolution in HCC  | <i>Valerie Chew (Duke-NUS Medical School, Singapore)</i>                                  |
| 13:30-13:50        | Pathological and Molecular Features Related to Cancer Stemness of HCC        | <i>Young Nyun Park (Yonsei Univ., Seoul)</i>                                              |
| 13:50-14:10        | HCC Genomics Using Single Cell Analysis                                      | <i>Irene Ng (The Univ. of Hong Kong, Hong Kong)</i>                                       |
| 14:10-14:30        | Discussion                                                                   |                                                                                           |
| 14:30-14:50        | Break                                                                        |                                                                                           |
| <b>14:50-16:10</b> | <b>Session 7. Imaging Diagnosis of HCC</b>                                   | <i>Choon Hua Thng (National Cancer Centre Singapore, Singapore)</i>                       |
| 14:50-15:10        | LI-RADS: Pitfalls and Problems or How to Use LR-M and Ancillary Features     | <i>Victoria Chernyak (Albert Einstein College of Medicine, New York)</i>                  |
| 15:10-15:25        | MR Imaging Phenotype of HCC and Histologic Correlation                       | <i>Jin-Young Choi (Yonsei Univ., Seoul)</i>                                               |
| 15:25-15:45        | Application of Radiomics for Primary Liver Cancer                            | <i>Seung Soo Lee (Univ. of Ulsan, Seoul)</i>                                              |
| 15:45-16:00        | AI for the Prediction, Diagnosis, and Treatment of HCC                       | <i>Jeong-Hoon Lee (Seoul National Univ., Seoul)</i>                                       |
| 16:00-16:10        | Discussion                                                                   |                                                                                           |



# The 11<sup>th</sup> Asia-Pacific Primary Liver Cancer Expert Meeting

## PROGRAM AT A GLANCE

GMT+09:00 (Seoul, Tokyo)

| Sunday, August 15, 2021 |                                                                                      |                                                           | GMT+09:00 (Seoul, Tokyo) |
|-------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------|--------------------------|
|                         | ROOM 1                                                                               | ROOM 2                                                    |                          |
| 08:00                   | Satellite Symposium - Eisai<br>(08:00-09:00)                                         |                                                           |                          |
| 09:00                   |                                                                                      |                                                           |                          |
| 10:00                   | Session 8<br>Multidisciplinary Approach in<br>Vascular Invasive HCC<br>(09:00-10:30) | Session 9<br>Cholangiocarcinoma<br>(09:00-10:10)          |                          |
| 11:00                   | Session 10<br>Systemic Therapy<br>for Advanced HCC<br>(10:40-12:10)                  | Session 11<br>Abstract Oral Presentation<br>(10:40-12:00) |                          |
| 12:00                   | State-of-the-Art Lecture 2<br>(12:10-12:50)                                          |                                                           |                          |
| 13:00                   | Wrap-up and Closing (12:50-13:00)                                                    |                                                           |                          |
| 14:00                   |                                                                                      |                                                           |                          |





|                    |                                                                       |                                                                                                                  |
|--------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| 08:00-09:00        | Satellite Symposium - Eisai                                           |                                                                                                                  |
| <b>09:00-10:30</b> | <b>Session 8. Multidisciplinary Approach in Vascular Invasive HCC</b> | <i>Kwang-Hyub Han (NECA, Seoul),<br/>Norihiro Kokudo (National Center for Global Health and Medicine, Tokyo)</i> |
| 09:00-09:20        | Hepatologist Perspectives                                             | <i>Jeong Won Jang (The Catholic Univ. of Korea, Seoul)</i>                                                       |
| 09:20-09:40        | Surgeon Perspectives                                                  | <i>Norihiro Kokudo (National Center for Global Health and Medicine, Tokyo)</i>                                   |
| 09:40-10:00        | Interventional Oncologist Perspectives                                | <i>Chien-An Liu (Taipei Veterans General Hospital, Taipei)</i>                                                   |
| 10:00-10:20        | Radiation Oncologist Perspectives                                     | <i>Laura Dawson (Univ. of Toronto, Toronto)</i>                                                                  |
| 10:20-10:30        | Discussion                                                            |                                                                                                                  |
| 10:30-10:40        | Break                                                                 |                                                                                                                  |
| <b>10:40-12:10</b> | <b>Session 10. Systemic Therapy for Advanced HCC</b>                  | <i>Sheng-Long Ye (Fudan Univ., Shanghai),<br/>Masatoshi Kudo (Kindai Univ., Osaka)</i>                           |
| 10:40-11:00        | Therapy of HCC: What Will Be the Next                                 | <i>Ann-Lii Cheng (National Taiwan Univ., Taipei)</i>                                                             |
| 11:00-11:20        | Tumor Immune Microenvironment-Based Immunotherapy                     | <i>Ghassan Abou-Alfa (Memorial Sloan-Kettering Cancer Center, New York)</i>                                      |
| 11:20-11:40        | Combination Immunotherapy with Anti-VEGF Multikinase Inhibitor        | <i>Richard Finn (Univ. of California LA, LA)</i>                                                                 |
| 11:40-12:00        | Combination Immunotherapy with Anti-CTLA-4 Antibody                   | <i>Thomas Yau (The Univ. of Hong Kong, Hong Kong)</i>                                                            |
| 12:00-12:10        | Discussion                                                            |                                                                                                                  |
| <b>12:10-12:50</b> | <b>State-of-the-Art Lecture 2</b>                                     | <i>Jinsil Seong (Yonsei Univ., Seoul)</i>                                                                        |
|                    | Radiation and Checkpoint Blockade Immunotherapy                       | <i>Andrew Sharabi (The Univ. California San Diego, San Diego)</i>                                                |
| 12:50-13:00        | Wrap-up and Closing                                                   |                                                                                                                  |

|                                                           |                                                                                                                                                                         |                                                                                                                    |
|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| <b>09:00-10:10 Session 9. Cholangiocarcinoma</b>          |                                                                                                                                                                         | <i>Chiun Hsu (National Taiwan Univ., Taipei),<br/>Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)</i> |
| 09:00-09:20                                               | Update of Combined Hepatocellular-Cholangiocarcinoma                                                                                                                    | <i>Matthew M. Yeh (Univ. of Washington, Seattle)</i>                                                               |
| 09:20-09:40                                               | Progress of Chemotherapy and Targeted Therapy in Cholangiocarcinoma                                                                                                     | <i>Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)</i>                                                |
| 09:40-10:00                                               | Immunotherapy for Cholangiocarcinoma: Hope or Hype?                                                                                                                     | <i>Andrew Zhu (Jiahui International Cancer Center, Shanghai)</i>                                                   |
| 10:00-10:10                                               | Discussion                                                                                                                                                              |                                                                                                                    |
| 10:10-10:40                                               | Break                                                                                                                                                                   |                                                                                                                    |
| <b>10:40-12:00 Session 11. Abstract Oral Presentation</b> |                                                                                                                                                                         | <i>Chih-Hung Hsu (National Taiwan Univ., Taipei),<br/>Do Young Kim (Yonsei Univ., Seoul)</i>                       |
| 10:40-10:50                                               | Comparisons of Three Serum Biomarkers Alone and in Combination for Detection of HCC in Patients with Nonalcoholic Fatty Liver Disease: A Multicenter Case-Control Study | <i>Tian Yang (Second Military Medical Univ., Shanghai)</i>                                                         |
| 10:50-11:00                                               | Single-Cell RNA Sequencing Shows the Immunosuppressive Landscape and Tumor Heterogeneity of HBV-Associated HCC                                                          | <i>Daniel Wai-Hung Ho (Univ. of Hong Kong, Hong Kong)</i>                                                          |
| 11:00-11:10                                               | Liver Transplantation vs Partial Hepatectomy for Stage T2 Multifocal HCC: A Propensity-Score Matched Analysis                                                           | <i>Kliment Bozhilov (Queen's Medical Center, Hawaii)</i>                                                           |
| 11:10-11:20                                               | Combined Stereotactic Body Radiotherapy (SBRT) and Immunotherapy vs SBRT in Locally Advanced HCC: Propensity Score Matching Analysis                                    | <i>Chiang Chi Leung (Univ. of Hong Kong, Hong Kong)</i>                                                            |
| 11:20-11:30                                               | Stereotactic Ablative Body Radiotherapy for Oligometastatic HCC: A Multi-Institutional Retrospective Study (KROG 20-04)                                                 | <i>Tae Hyung Kim (Eulji Univ., Seoul)</i>                                                                          |
| 11:30-11:40                                               | Transcatheter Arterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable HCC (TACTICS-L) in Japan: Interim Analysis       | <i>Issei Saeki (Yamaguchi Univ., Yamaguchi)</i>                                                                    |
| 11:40-11:50                                               | IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib by Baseline Varices Status in Patients with HCC                                           | <i>Philippe Merle (Hospital La Croix-Rousse, Lyon)</i>                                                             |
| 11:50-12:00                                               | Nivolumab Plus Ipilimumab (N+I) as Neoadjuvant Therapy for Potentially Resectable HCC                                                                                   | <i>Yung-Yeh Su (National Health Research Institute, Taiwan)</i>                                                    |